Objectives: To identify clinicopathologic predictors that can accurately stratify sentinel lymph node biopsy-negative melanoma patients by risk of progression, to improve prognostic accuracy and guide personalised treatment decisions.
Introduction: Recent approval of adjuvant pembrolizumab for resected stage IIB/IIC melanoma necessitates tools to precisely stratify high versus low risk patients, to guide treatment decisions and prevent inappropriate immunotherapy toxicity. Using multivariable analyses, this study demonstrates that tumor-infiltrating lymphocyte scoring effectively distinguishes high and low risk subgroups, offering a cost-effective method of guiding personalised treatment decisions.
Materials / method: Multicenter, retrospective cohort study of 1229 cutaneous melanoma patients treated at 2 UK hospitals between 2004-2017, who underwent SLNB. TIL score, Breslow thickness, ulceration, SLNB status, and other clinicopathological factors were examined as potential predictors using Kaplan-Meier curves, univariate analyses, multivariable logistic regression and Cox proportional hazards modeling. Progression was defined as recurrence at local, intransit, regional or distant sites. Regression model fit was assessed by -2 log likelihood, overall chi-square statistics and Hosmer-Lemeshow goodness of fit
Results: The median follow-up duration was 9.5 years, during which the melanoma progression rate after SLNB was 20%. In SLNB-negative patients, TIL score and Breslow thickness were the strongest independent predictors of progression in multivariate analyses. Non-brisk TILs were associated with three-fold higher progression risk and lower progression-free survival compared to absent (p=0.003) or brisk TILs, particularly in stage II patients. Non-brisk TILs and Breslow thickness >2mm identified a high-risk subgroup. In these patients, progression-free survival was 20% lower in males than females (p<0.001
Conclusion: Breslow and TIL scores interact to reliably predict PFS in SLNB-negative melanoma and discriminate between high and low-risk stage II patients. Incorporating SLNB and TIL statuses in prognostic tools holds promise for identifying high-risk patients who may benefit from adjuvant immunotherapy and low-risk patients who may safely forego it.
Divulgação de informações
Você recebeu algum patrocínio para sua pesquisa neste tema?
Não
Você recebeu algum tipo de honorário, pagamento ou outra forma de compensação por seu trabalho neste estudo?
Não
Você possui relação financeira com alguma entidade que possa competir com os medicamentos, materiais ou instrumentos abordados no seu estudo?
Não
Você detém ou pediu a registro de patente para algum dos instrumentos, medicamentos ou materiais abordados no seu estudo?
Não
Este trabalho não recebeu nenhum patrocínio direto ou indireto. O mesmo está sob a própria responsabilidade do seu autor.